文献引用
-
1) The Combination of Platelet Rich Plasma Gel, Human Umbilical Mesenchymal Stem Cells and Nanohydroxyapatite/polyamide 66 Promotes Angiogenesis and Bone Regeneration in Large Bone Defect.
-
2) Extracellular HSP90α promotes cellular senescence by modulating TGF‐β signaling in pulmonary fibrosis.
-
3) Loss of MBD2 ameliorates LPS-induced alveolar epithelial cell apoptosis and ALI in mice via modulating intracellular zinc homeostasis.
-
4) Increased B Cell-Activating Factor Expression Is Associated with Postoperative Recurrence of Chronic Rhinosinusitis with Nasal Polyps.
-
5) TMEM100 Regulates Neuropathic Pain by Reducing the Expression of Inflammatory Factors.
-
6) CircRNA_45478 promotes ischemic AKI by targeting the miR-190a-5p/PHLPP1 axis.
-
7) Indole-3-acetic acid improves the hepatic mitochondrial respiration defects by PGC1a up-regulation.
-
8) Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics.
-
9) Zebrafish cox17 modulates primitive erythropoiesis via regulation of mitochondrial metabolism to facilitate hypoxia tolerance.
-
10) Atractylenolide III Improves Mitochondrial Function and Protects Against Ulcerative Colitis by Activating AMPK/SIRT1/PGC-1 α.
-
11) HDM induce airway epithelial cell ferroptosis and promote inflammation by activating ferritinophagy in asthma.
-
12) Resveratrol ameliorates learning and memory impairments induced by bilateral hippocampal injection of streptozotocin in mice.
-
13) Transforming growth factor-β receptor type 2 is required for heparin-binding protein-induced acute lung injury and vascular leakage for transforming growth factor-β/Smad/Rho signaling pathway activation.
-
14) Transforming growth factor-β receptor type 2 is required for heparin-binding protein-induced acute lung injury and vascular leakage for transforming growth factor-β/Smad/Rho signaling pathway activation.
-
15) MicroRNA-483-5p inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells by targeting the RPL31-mediated RAS/MEK/ERK signaling pathway.